<DOC>
	<DOCNO>NCT00479895</DOCNO>
	<brief_summary>The test compound subject clinical trial haemoglobin-based oxygen carrier , HBOC-201 ( Hemopure ) . HBOC-201 , initially develop alternative red blood cell surgical patient , ability restore tissue oxygenation persistently ischemic tissue . The development new class compound , refer oxygen therapeutic , provide opportunity test safety efficacy new approach management myocardial ischemia .</brief_summary>
	<brief_title>Hemoglobin Based Oxygen Therapeutics Elective Percutaneous Coronary Revascularization</brief_title>
	<detailed_description>Because ability perfuse deliver oxygen , hemoglobin-based oxygen carrier ( HBOC ) may consider treatment several ischemic condition , acute coronary syndrome ( ACS ) . Elective percutaneous intervention ( PCI ) induce transient myocardial ischemia due reduction coronary flow balloon inflation coronary artery , thus simulate control setting , occurrence ACS .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>HBOC 201</mesh_term>
	<criteria>Signed informed consent initiation studyrelated procedure agreement comply protocolspecific procedure Stable angina pectoris ( CCS Class 1 , 2 , 3 , 4 ) unstable angina ( Braundwald class 13 , B ) document silent ischemia Baseline ECG stable sinus rhythm sign ischemia Q wave , bundle branch block IV conduction disturbance . Normal leave ventricular wall motion leave ventricular angiogram echocardiogram preserve systolic global LV function Nonocclusive stenosis , locate proximal segment leave anterior descend artery ( LAD ) ( segment 6 and/or 7 ) and/or circumflex artery ( CFX ) ( segment 11 and/or 12 ) right coronary artery ( RCA ) ( segment 1 , 2 and/or 3 ) clinical indication percutaneous treatment coronary stenting Successful PCI stenting target vessel Older 18 year younger 80 year age Active ischemia initiation study procedure NonST segment elevation myocardial infarction History ECG evidence prior MI territory supply vessel undergoing PCI , IV conduction defects/baseline STsegment abnormalities surface ECG Moderate severe aortic mitral valve disease Evidence LV hypertrophy echocardiogram IVS &gt; 13 and/or PW &gt; 13mm Angiographically visible collateral vessel target vessel Hypertension adequately control antihypertensive therapy time study entry ( &gt; 140/100mmHg ) Uncompensated congestive heart failure sign pulmonary edema Significant hemodynamic compromise and/or cardiogenic shock require inotropic pressor support Contraindications standard drug coronary intervention coronary heart disease : aspirin , heparin , low molecular weight heparin , clopidogrel , contrast dye Confirmed pregnancy Systemic mastocytosis Hypoxemia ( need mechanical ventilation Known history COPD FEV 1 &lt; 1.0 liter Renal impairment : creatinine &gt; 1.6 mg/dl Participation another trial investigational drug device include followup period , within last 30 day enrollment Additional exclusion criterion end PCI ( randomization ) Coronary TIMI flow treat artery less 3 Serious arrhythmia during/following PCI note Coronary spasm follow PCI Any deterioration subject 's `` risk '' status inform consent randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Balloon Occlusion</keyword>
	<keyword>Catheter Lab</keyword>
</DOC>